Skip to content

Randomized clinical trial to evaluate the efficacy of fibrin membrane graft with eye drops concentrated in autologous growth factors in primary pterygium surgery compared to amniotic membrane graft in terms of recurrence during the first year after surgery.

Status
Not yet recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-520640-15-00
Enrollment
110
Registered
2025-01-30
Start date
Unknown
Completion date
Unknown
Last updated
2025-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pterygium

Brief summary

Recurrence rate in both techniques. Defined as the number of recurrences per technique divided by the surgeries performed with amniotic membrane implant and those using fibrin-rich growth factor graft. Recurrence is understood as the appearance of fibrovascular proliferation invading the corneal limbus and the cornea. This will be evaluated during follow-up at one month, two months, three months, six months, and one year after the intervention.

Interventions

Sponsors

Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Design outcomes

Primary

MeasureTime frame
Recurrence rate in both techniques. Defined as the number of recurrences per technique divided by the surgeries performed with amniotic membrane implant and those using fibrin-rich growth factor graft. Recurrence is understood as the appearance of fibrovascular proliferation invading the corneal limbus and the cornea. This will be evaluated during follow-up at one month, two months, three months, six months, and one year after the intervention.

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026